{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:17:47Z","timestamp":1788337067425,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Solid organ transplant recipients face high fracture risk with limited evidence guiding anabolic therapy. In this real-world cohort, teriparatide was associated with significant improvements in bone mineral density and acceptable safety without adverse graft effects. These findings support selective anabolic treatment in high-risk transplant recipients and highlight the need for prospective studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Solid organ transplant (SOT) recipients are at high risk for osteoporosis and fragility fractures due to pre-existing organ dysfunction and long-term immunosuppressive therapy, particularly glucocorticoids. However, evidence supporting the use of anabolic osteoporosis therapy in this population remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at a large transplant center including adult kidney, lung, and liver transplant recipients selected for teriparatide treatment based on clinical indications for severe post-transplant osteoporosis for at least 3 months. Bone mineral density (BMD), incident fractures, biochemical parameters, renal function, and adverse events were evaluated during treatment and follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-nine SOT recipients (33% men; mean age 61.3\u2009\u00b1\u200911.6\u00a0years) were included, comprising kidney (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910), lung (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), and liver (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099) transplant recipients. Prior fragility fractures were present in 90% of patients, and 79% had multiple fractures. Median teriparatide treatment duration was 22.3\u00a0months. Significant increases in BMD were observed at the lumbar spine (+11\u2009\u00b1\u200915%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), femoral neck (+8\u2009\u00b1\u200914%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05), and total hip (+11\u2009\u00b1\u200916%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05). Six patients sustained fractures after teriparatide initiation; only two occurred during active therapy, whereas four occurred after treatment discontinuation. Hypercalcemia occurred in one patient and led to treatment cessation. The estimated glomerular filtration rate declined modestly during the first 6 months and stabilized thereafter; a broadly similar pattern was observed in contemporaneous matched transplant controls. No episodes of graft rejection were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world cohort of SOT recipients with severe osteoporosis, teriparatide therapy was associated with significant improvements in BMD, acceptable safety, and no apparent excess risk to graft function. These findings support the selective use of anabolic therapy in high-risk transplant recipients and highlight the need for prospective studies to define optimal treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01751-4","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:43:29Z","timestamp":1788335009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Teriparatide treatment of osteoporosis in solid organ transplant recipients\u2014a single-center experience"],"prefix":"10.1007","volume":"21","author":[{"given":"Talia","family":"Diker Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Shraga-Slutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Kaminer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gorshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idit","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tsvetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1751_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bone.2019.07.006","volume":"127","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Tsourdi E, Makras P, Polyzos SA, Meier C, McCloskey EV, Pepe J, Zillikens MC (2019) Bone disease following solid organ transplantation: a narrative review and recommendations for management from The European Calcified Tissue Society. Bone 127:401\u2013418","journal-title":"Bone"},{"key":"1751_CR2","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley L, Humphrey MB (2018) Glucocorticoid-induced osteoporosis. N Engl J Med 379:2547\u20132556","journal-title":"N Engl J Med"},{"key":"1751_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo MR, Dipchand A, Starling R et al (2010) The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29:914\u2013956","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 3","key":"1751_CR4","first-page":"S1","volume":"9","author":"Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","unstructured":"Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1\u2013S157","journal-title":"Am J Transplant"},{"key":"1751_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/lt.23566","volume":"19","author":"MR Lucey","year":"2013","unstructured":"Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW (2013) Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 19:3\u201326","journal-title":"Liver Transpl"},{"key":"1751_CR6","volume":"10","author":"SC Palmer","year":"2019","unstructured":"Palmer SC, Chung EY, McGregor DO, Bachmann F, Strippoli GF (2019) Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 10:Cd005015","journal-title":"Cochrane Database Syst Rev"},{"key":"1751_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"1751_CR8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226","journal-title":"N Engl J Med"},{"key":"1751_CR9","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039","journal-title":"N Engl J Med"},{"key":"1751_CR10","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","volume":"8","author":"D Cejka","year":"2008","unstructured":"Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, Haas M (2008) Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 8:1864\u20131870","journal-title":"Am J Transplant"},{"key":"1751_CR11","doi-asserted-by":"publisher","first-page":"luae026","DOI":"10.1210\/jcemcr\/luae026","volume":"2","author":"LM Raven","year":"2024","unstructured":"Raven LM, Goodall L, Center JR, Muir CA (2024) Teriparatide as treatment for severe osteoporosis in lung transplant recipients. JCEM Case Rep 2:luae026","journal-title":"JCEM Case Rep"},{"key":"1751_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00198-016-3858-2","volume":"28","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Wagner D, Krisper P, Amrein K, Dimai H (2017) Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report. Osteoporos Int 28:1149\u20131152","journal-title":"Osteoporos Int"},{"key":"1751_CR13","first-page":"451","volume":"15","author":"Z Qiu","year":"2021","unstructured":"Qiu Z, Lin C, Zhang Y, Lin C, Deng J, Wu M (2021) Analysis of the efficacy and safety of teriparatide and alendronate in the treatment of osteoporosis after renal transplantation. Iran J Kidney Dis 15:451\u2013456","journal-title":"Iran J Kidney Dis"},{"key":"1751_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/phar.70040","volume":"45","author":"SE January","year":"2025","unstructured":"January SE, Fester KA, Escamilla JE, Cano M (2025) Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation. Pharmacotherapy 45:495\u2013503","journal-title":"Pharmacotherapy"},{"key":"1751_CR15","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s11255-025-04383-8","volume":"57","author":"D Vetrano","year":"2025","unstructured":"Vetrano D, Aguanno F, Passaseo A, Barbuto S, Tondolo F, Catalano V, Zavatta G, Pagotto U, La Manna G, Cianciolo G (2025) Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience. Int Urol Nephrol 57:1965\u20131975","journal-title":"Int Urol Nephrol"},{"key":"1751_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247\u2013254","journal-title":"Ann Intern Med"},{"key":"1751_CR17","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/ndt\/gfh876","volume":"20","author":"Y Iwasaki-Ishizuka","year":"2005","unstructured":"Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M (2005) Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 20:1904\u20131911","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"1751_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/ndt\/11.supp3.58","volume":"11","author":"F Velasquez-Forero","year":"1996","unstructured":"Velasquez-Forero F, Mondrag\u00f3n A, Herrero B, Pe\u00f1a JC (1996) Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 11(Suppl 3):58\u201364","journal-title":"Nephrol Dial Transplant"},{"key":"1751_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/ctr.12622","volume":"29","author":"T Hod","year":"2015","unstructured":"Hod T, Riella LV, Chandraker A (2015) Recombinant PTH therapy for severe hypoparathyroidism after kidney transplantation in pre-transplant parathyroidectomized patients: review of the literature and a case report. Clin Transplant 29:951\u2013957","journal-title":"Clin Transplant"},{"key":"1751_CR20","first-page":"601","volume":"33","author":"L Le\u00f3n","year":"2013","unstructured":"Le\u00f3n L, Rial MC, Curcio D, Casadei D (2013) Teriparatide in kidney transplant patients with severe hypoparathyroidism. Nefrologia 33:601\u2013602","journal-title":"Nefrologia"},{"key":"1751_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1542-4758.2009.00380.x","volume":"13","author":"A Mahajan","year":"2009","unstructured":"Mahajan A, Narayanan M, Jaffers G, Concepcion L (2009) Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH. Hemodial Int 13:547\u2013550","journal-title":"Hemodial Int"},{"key":"1751_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/TP.0b013e3182247b98","volume":"92","author":"EL Nogueira","year":"2011","unstructured":"Nogueira EL, Costa AC, Santana A, Guerra JO, Silva S, Mil-Homens C, Costa AG (2011) Teriparatide efficacy in the treatment of severe hypocalcemia after kidney transplantation in parathyroidectomized patients: a series of five case reports. Transplantation 92:316\u2013320","journal-title":"Transplantation"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01751-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01751-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01751-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:43:31Z","timestamp":1788335011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01751-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01751-4","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"136"}}